デフォルト表紙
市場調査レポート
商品コード
1763961

医薬品有効成分（API）市場- 世界の産業規模、シェア、動向、機会、予測、合成タイプ別、用途別、地域別セグメント、競合、2020年～2030年

Active Pharmaceutical Ingredient Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type of Synthesis, By Application, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
医薬品有効成分（API）市場- 世界の産業規模、シェア、動向、機会、予測、合成タイプ別、用途別、地域別セグメント、競合、2020年～2030年
出版日: 2025年06月30日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

医薬品有効成分（API）の世界市場は、2024年に1,554億1,000万米ドルと評価され、2030年には2,276億7,000万米ドルに達すると予測され、予測期間中のCAGRは6.77%で成長します。

製薬会社ががん、心血管疾患、神経疾患、糖尿病、呼吸器疾患など幅広い症状に対応するために治療ポートフォリオを拡大するにつれて、APIの需要は着実に増加しています。この急増は、慢性疾患の世界の負担増、人口の高齢化、ライフスタイルの進化によるところが大きいです。

市場概要
予測期間 2026-2030
市場規模：2024年 1,554億1,000万米ドル
市場規模：2030年 2,276億7,000万米ドル
CAGR：2025年～2030年 6.77%
急成長セグメント バイオテクノロジー
最大市場 北米

市場の情勢は、適正製造基準（GMP）と厳格な品質管理基準に焦点を当てた規制状況の強化によって形成されています。原薬メーカーは、先端技術への投資、プロセスの自動化の改善、環境の持続可能性の優先によって対応しています。世界サプライチェーンが多様化し続ける中、競争力を維持し医薬品セクターのダイナミックなニーズに応えようとするメーカーにとって、規制対応、インフラ、地理的回復力への戦略的投資は引き続き不可欠です。

主な市場促進要因

ヘルスケア産業の成長

主な市場課題

高い生産コスト

主な市場動向

ペプチドおよびオリゴヌクレオチドAPIの台頭

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界の医薬品有効成分（API）市場に与える影響

第5章 世界の医薬品有効成分（API）市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 合成タイプ別（バイオテクノロジー、発酵、植物抽出物、合成）
    • 用途別（心血管疾患、腫瘍学、神経疾患、整形外科疾患、呼吸器疾患、消化器疾患、泌尿器科、その他）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の医薬品有効成分（API）市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • メキシコ
    • カナダ

第7章 欧州の医薬品有効成分（API）市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の医薬品有効成分（API）市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第9章 南米の医薬品有効成分（API）市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの医薬品有効成分（API）市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品上市
  • 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界の医薬品有効成分（API）市場：SWOT分析

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.
  • GlaxoSmithKline Plc
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Sanofi S.A.
  • Eli Lilly and Company
  • AbbVie Inc

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 5062

The Global Active Pharmaceutical Ingredient (API) Market was valued at USD 155.41 Billion in 2024 and is projected to reach USD 227.67 Billion by 2030, growing at a CAGR of 6.77% during the forecast period. Demand for APIs is rising steadily as pharmaceutical companies broaden their therapeutic portfolios to address a wide array of conditions including oncology, cardiovascular ailments, neurological disorders, diabetes, and respiratory diseases. This surge is largely driven by the growing global burden of chronic illnesses, an aging population, and evolving lifestyle factors.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 155.41 Billion
Market Size 2030USD 227.67 Billion
CAGR 2025-20306.77%
Fastest Growing SegmentBiotech
Largest MarketNorth America

The market landscape is being shaped by increasing regulatory scrutiny focused on Good Manufacturing Practices (GMP) and stringent quality control standards. API manufacturers are responding by investing in advanced technologies, improving process automation, and prioritizing environmental sustainability. As global supply chains continue to diversify, strategic investment in regulatory compliance, infrastructure, and geographic resilience will remain essential for manufacturers seeking to maintain competitiveness and meet the dynamic needs of the pharmaceutical sector.

Key Market Drivers

Growth in Healthcare Industry

The continued expansion of the global healthcare sector is a primary catalyst for growth in the API market. With healthcare spending exceeding USD 4 trillion annually, pharmaceuticals and biotechnology account for a significant portion-over USD 850 billion-underscoring the vital role APIs play in medical innovation and treatment delivery.

The escalating prevalence of chronic conditions such as cardiovascular diseases, cancer, and diabetes has led to a sharp increase in demand for high-quality, effective APIs. In 2021, noncommunicable diseases (NCDs) accounted for around 43 million deaths worldwide, representing approximately 75% of all non-pandemic-related fatalities. These health burdens drive the need for long-term medication use, prompting pharmaceutical companies to ramp up API production to meet growing therapeutic demands. The development of biologics and high-potency APIs (HPAPIs) further reflects the healthcare sector's focus on targeted, personalized treatments, reinforcing sustained market growth.

Key Market Challenges

High Cost of Production

High production costs present a substantial barrier in the global API market, affecting both manufacturer margins and the affordability of end products. These costs stem from intricate synthesis procedures, rigorous quality and safety requirements, and the rising expense of sourcing raw materials.

Complying with Good Manufacturing Practices (GMP) mandates the use of highly specialized equipment, skilled personnel, and continuous quality assurance efforts, significantly elevating both capital and operational expenditures-particularly in developed markets. Additionally, maintaining consistent output quality, ensuring regulatory compliance, and managing environmentally sustainable operations add further financial strain. This economic burden restricts entry for smaller firms and contributes to price volatility, especially in regions with limited manufacturing infrastructure.

Key Market Trends

Rise of Peptide and Oligonucleotide APIs

A prominent trend shaping the API market is the surge in demand for peptide and oligonucleotide APIs, driven by the global push toward precision medicine and biologically targeted therapies. GLP-1 analogs like semaglutide and liraglutide are gaining attention in the generics segment, particularly for their effectiveness in treating diabetes and obesity.

Peptides, with their high specificity and minimal toxicity, are increasingly used in treating cancers and metabolic or rare genetic disorders. Likewise, oligonucleotide APIs, composed of DNA or RNA sequences, allow for therapeutic targeting at the genetic level, opening new treatment avenues for diseases previously considered intractable. These innovations support the pharmaceutical industry's pivot to high-efficacy treatments, marking a shift from conventional small-molecule drugs to advanced, biologically complex APIs.

Key Market Players

  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Merck & Co., Inc.
  • GlaxoSmithKline Plc
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Sanofi S.A.
  • Eli Lilly and Company
  • AbbVie Inc

Report Scope

In this report, the Global Active Pharmaceutical Ingredient Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Active Pharmaceutical Ingredient Market, By Type of Synthesis:

  • Biotech
  • Fermentation
  • Plant Extracts
  • Synthetic

Active Pharmaceutical Ingredient Market, By Application:

  • Cardiovascular Disease
  • Oncology
  • Neurological Disorders
  • Orthopedic Disorders
  • Respiratory
  • Gastrointestinal Disorders
  • Urology
  • Others

Active Pharmaceutical Ingredient Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Active Pharmaceutical Ingredient Market.

Available Customizations

Global Active Pharmaceutical Ingredient Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Active Pharmaceutical Ingredient Market

5. Global Active Pharmaceutical Ingredient Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type of Synthesis (Biotech, Fermentation, Plant Extracts, Synthetic)
    • 5.2.2. By Application (Cardiovascular Disease, Oncology, Neurological Disorders, Orthopedic Disorders, Respiratory, Gastrointestinal Disorders, Urology, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Active Pharmaceutical Ingredient Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type of Synthesis
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Active Pharmaceutical Ingredient Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type of Synthesis
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Active Pharmaceutical Ingredient Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type of Synthesis
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Active Pharmaceutical Ingredient Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type of Synthesis
        • 6.3.3.2.2. By Application

7. Europe Active Pharmaceutical Ingredient Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type of Synthesis
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Active Pharmaceutical Ingredient Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type of Synthesis
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Active Pharmaceutical Ingredient Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type of Synthesis
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Active Pharmaceutical Ingredient Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type of Synthesis
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Active Pharmaceutical Ingredient Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type of Synthesis
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Active Pharmaceutical Ingredient Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type of Synthesis
        • 7.3.5.2.2. By Application

8. Asia Pacific Active Pharmaceutical Ingredient Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type of Synthesis
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Active Pharmaceutical Ingredient Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type of Synthesis
        • 8.3.1.2.2. By Application
    • 8.3.2. India Active Pharmaceutical Ingredient Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type of Synthesis
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Active Pharmaceutical Ingredient Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type of Synthesis
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Active Pharmaceutical Ingredient Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type of Synthesis
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Active Pharmaceutical Ingredient Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type of Synthesis
        • 8.3.5.2.2. By Application

9. South America Active Pharmaceutical Ingredient Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type of Synthesis
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Active Pharmaceutical Ingredient Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type of Synthesis
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Active Pharmaceutical Ingredient Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type of Synthesis
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Active Pharmaceutical Ingredient Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type of Synthesis
        • 9.3.3.2.2. By Application

10. Middle East and Africa Active Pharmaceutical Ingredient Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type of Synthesis
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Active Pharmaceutical Ingredient Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type of Synthesis
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Active Pharmaceutical Ingredient Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type of Synthesis
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Active Pharmaceutical Ingredient Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type of Synthesis
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Active Pharmaceutical Ingredient Market: SWOT Analysis

15. Porters Five Forces Analysis

  • 15.1. Competition in the Industry
  • 15.2. Potential of New Entrants
  • 15.3. Power of Suppliers
  • 15.4. Power of Customers
  • 15.5. Threat of Substitute Products

16. Competitive Landscape

  • 16.1. Teva Pharmaceutical Industries Ltd.
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (As Reported)
    • 16.1.5. Recent Developments
    • 16.1.6. Key Personnel Details
    • 16.1.7. SWOT Analysis
  • 16.2. Bristol-Myers Squibb Company
  • 16.3. Boehringer Ingelheim GmbH
  • 16.4. Merck & Co., Inc.
  • 16.5. GlaxoSmithKline Plc
  • 16.6. Novartis International AG
  • 16.7. F. Hoffmann-La Roche AG
  • 16.8. Sanofi S.A.
  • 16.9. Eli Lilly and Company
  • 16.10. AbbVie Inc

17. Strategic Recommendations

18. About Us & Disclaimer